
Vamifeport
CAS No. 2095668-10-1
Vamifeport ( —— )
产品货号. M35124 CAS No. 2095668-10-1
VIT-2763 是具有口服活性的铁转运蛋白 (ferroportin) 的抑制剂,抑制hepcidin 与铁转运蛋白结合,阻滞铁外流。VIT-2763有用于地中海贫血症的潜力。
纯度: >98% (HPLC)






规格 | 价格/人民币 | 库存 | 数量 |
2MG | ¥1512 | 有现货 |
![]() ![]() |
5MG | ¥2334 | 有现货 |
![]() ![]() |
10MG | ¥3674 | 有现货 |
![]() ![]() |
25MG | ¥6006 | 有现货 |
![]() ![]() |
50MG | ¥8446 | 有现货 |
![]() ![]() |
100MG | ¥11093 | 有现货 |
![]() ![]() |
500MG | 获取报价 | 有现货 |
![]() ![]() |
1G | 获取报价 | 有现货 |
![]() ![]() |
生物学信息
-
产品名称Vamifeport
-
注意事项本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
-
产品简述VIT-2763 是具有口服活性的铁转运蛋白 (ferroportin) 的抑制剂,抑制hepcidin 与铁转运蛋白结合,阻滞铁外流。VIT-2763有用于地中海贫血症的潜力。
-
产品描述VIT-2763, an oral ferroportin inhibitor, inhibits hepcidin binding to ferroportin and blocks iron efflux. VIT-2763 has the potential in the treatment of β-thalassemia.
-
体外实验VIT-2763 dose dependently reduces the fluorescence polarization signal, indicating that VIT-2763 displaces TMR-hepcidin from ferroportin (IC50 of 24 ± 13 nM).VIT-2763 induces BLA reporter gene activity with an average EC50 of 140 ± 50 nM, as a consequence of increasing intracellular iron concentrations caused by blocked iron export in HEK293 cells.VIT-2763 (100 nM) triggers ubiquitination and subsequent internalization and degradation of ferroportin.Cell Viability Assay.Cell Line:J774 cells. Concentration:100 nM.Incubation Time:10, 20, 40, 60, or 120 minutes.Result:Induced ferroportin internalization and ubiquitination.
-
体内实验VIT-2763 (30, 100 mg/kg, orally twice daily for 36 days) decreases serum iron and prevented liver iron loading in Hbbth3/+ mice.VIT-2763 did not change the total liver iron.VIT-2763 (30, 100 mg/kg, orally twice daily for 36 days) significantly corrects anemia and improved RBC parameters in Hbbth3/+ mice. VIT-2763 decreases the percentage of ROS-positive RBCs in Hbbth3/+ mice from 67% to 30%.VIT-2763 decreases apoptosis and extends the life span of RBCs in Hbbth3/+ mice.Animal Model:Hbbth3/+ mice.Dosage:30, 100 mg/kg.Administration:Orally twice daily for 36 days.Result:Significantly decreased serum iron levels by 77% (30 mg/kg) and 84% (100 mg/kg),Significantly increased Hb levels (as of day 8 of treatment), RBC counts, mean corpuscular Hb concentration (MCHC), and significantly lowered reticulocyte counts, mean corpuscular Hb (MCH), mean corpuscular volume (MCV), and RBC distribution width (RDW) in Hbbth3/+ mice, as compared with the Hbbth3/+ vehicle group.
-
同义词——
-
通路Apoptosis
-
靶点Ferroptosis
-
受体Ferroptosis
-
研究领域——
-
适应症——
化学信息
-
CAS Number2095668-10-1
-
分子量408.43
-
分子式C21H21FN6O2
-
纯度>98% (HPLC)
-
溶解度In Vitro:?DMSO 中的溶解度 : 83.33 mg/mL (204.03 mM; 超声助溶 )
-
SMILESFc1cccnc1CNC(=O)c1coc(CCNCCc2nc3ccccc3[nH]2)n1
-
化学全称——
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1. Vania Manolova, et al. Oral Ferroportin Inhibitor Ameliorates Ineffective Erythropoiesis in a Model of β-Thalassemia. J Clin Invest. 2019 Dec 9;130(1):491-506.?
产品手册




关联产品
-
BCP-T.A
BCP-T.A,一种杂环亲电子试剂,通过与 GPX4 结合而有效地诱导铁死亡 (ferroptosis)。BCP-T.A 是一种点击化学试剂。它含有 Alkyne 基团,可以和含有 Azide 基团的分子发生铜催化的叠氮-炔环加成反应 (CuAAc)。
-
Cerivastatin
Cerivastatin 是一种合成的降脂剂,是一种高效,耐受性好,口服活性的 HMG-CoA 还原酶抑制剂,Ki 为 1.3 nM/L。Cerivastatin 可降低低密度脂蛋白胆固醇水平。Cerivastatin 还主要通过 RhoA 抑制作用来抑制 MDA-MB-231 细胞的增殖和侵袭,具有抗癌作用。
-
UAMC-3203 hydrochlor...
UAMC-3203 盐酸盐是一种有效的选择性铁死亡抑制剂,IC50 为 12 nM。